JP2024503372A5 - - Google Patents
Info
- Publication number
- JP2024503372A5 JP2024503372A5 JP2023541564A JP2023541564A JP2024503372A5 JP 2024503372 A5 JP2024503372 A5 JP 2024503372A5 JP 2023541564 A JP2023541564 A JP 2023541564A JP 2023541564 A JP2023541564 A JP 2023541564A JP 2024503372 A5 JP2024503372 A5 JP 2024503372A5
- Authority
- JP
- Japan
- Prior art keywords
- mds
- pharmaceutical composition
- composition according
- tascinimod
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21152018 | 2021-01-18 | ||
| EP21152018.4 | 2021-01-18 | ||
| EP21201509.3 | 2021-10-07 | ||
| EP21201509 | 2021-10-07 | ||
| EP21205665 | 2021-10-29 | ||
| EP21205665.9 | 2021-10-29 | ||
| PCT/EP2022/050891 WO2022152902A1 (en) | 2021-01-18 | 2022-01-17 | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024503372A JP2024503372A (ja) | 2024-01-25 |
| JP2024503372A5 true JP2024503372A5 (enExample) | 2025-01-16 |
| JP7837338B2 JP7837338B2 (ja) | 2026-03-30 |
Family
ID=80034981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541564A Active JP7837338B2 (ja) | 2021-01-18 | 2022-01-17 | 骨髄異形成症候群の処置における使用のためのタスキニモドまたはその薬学的に許容される塩 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240091215A1 (enExample) |
| EP (1) | EP4277628B1 (enExample) |
| JP (1) | JP7837338B2 (enExample) |
| KR (1) | KR20230133317A (enExample) |
| AU (1) | AU2022208424A1 (enExample) |
| CA (1) | CA3204120A1 (enExample) |
| ES (1) | ES3057099T3 (enExample) |
| IL (1) | IL304232A (enExample) |
| MX (1) | MX2023008016A (enExample) |
| PL (1) | PL4277628T3 (enExample) |
| WO (1) | WO2022152902A1 (enExample) |
| ZA (1) | ZA202307855B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240012436A (ko) | 2021-05-25 | 2024-01-29 | 액티브 바이오테크 에이비 | 복수의 타스퀴니모드 입자 및 그 용도 |
| WO2024137713A1 (en) * | 2022-12-20 | 2024-06-27 | Constellation Pharmaceuticals, Inc. | Methods for treating lower risk myelodysplastic syndrome |
| CN122272585A (zh) * | 2026-05-08 | 2026-06-26 | 吉林大学 | 他喹莫德在制备用于调控淋巴管炎症反应的药物中的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| WO2012004338A1 (en) | 2010-07-09 | 2012-01-12 | Active Biotech Ab | Method for manufacturing of quinoline-3-carboxamides |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| SI3016512T1 (sl) | 2013-07-05 | 2020-07-31 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Topni CD33 za zdravljenje mielodisplastičnih sindromov (MDS) |
| SG11201607083VA (en) | 2014-02-28 | 2016-09-29 | Incyte Corp | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
| EP3041472B1 (en) * | 2014-09-23 | 2017-02-01 | Active Biotech AB | Quinoline carboxamides for use in the treatment of multiple myeloma |
| BR112017009854B1 (pt) | 2014-11-19 | 2022-08-23 | Active Biotech Ab | Uso do composto 4-hidroxi-5-metoxi-n,1-dimetil-2-oxo-n-[4-(trifluorometil)fenil]-1,2-dihidroquinolina-3-carboxamida (tasquinimod) ou um sal farmaceuticamente aceitável do mesmo para o tratamento de leucemia |
| EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
| US11801240B2 (en) | 2017-10-06 | 2023-10-31 | Tesaro, Inc. | Combination therapies and uses thereof |
| JP2019127473A (ja) | 2018-01-26 | 2019-08-01 | 学校法人同志社 | 多発性硬化症の治療及び／又は予防のための薬剤 |
-
2022
- 2022-01-17 WO PCT/EP2022/050891 patent/WO2022152902A1/en not_active Ceased
- 2022-01-17 AU AU2022208424A patent/AU2022208424A1/en active Pending
- 2022-01-17 MX MX2023008016A patent/MX2023008016A/es unknown
- 2022-01-17 EP EP22700096.5A patent/EP4277628B1/en active Active
- 2022-01-17 PL PL22700096.5T patent/PL4277628T3/pl unknown
- 2022-01-17 CA CA3204120A patent/CA3204120A1/en active Pending
- 2022-01-17 ES ES22700096T patent/ES3057099T3/es active Active
- 2022-01-17 JP JP2023541564A patent/JP7837338B2/ja active Active
- 2022-01-17 KR KR1020237026973A patent/KR20230133317A/ko active Pending
- 2022-01-17 US US18/272,326 patent/US20240091215A1/en active Pending
-
2023
- 2023-07-04 IL IL304232A patent/IL304232A/en unknown
- 2023-08-11 ZA ZA2023/07855A patent/ZA202307855B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110052547A1 (en) | Rapamycin-resistant t cells and therapeutic uses thereof | |
| CN115300624A (zh) | 人参皂苷联合pd-1阻断剂在制备抗头颈鳞癌药物中的应用 | |
| KR20230133317A (ko) | 골수이형성 증후군의 치료에 이용하기 위한 타스퀴니모드또는 이의 약제학적으로 허용가능한 염 | |
| KR102376846B1 (ko) | 수지상 세포를 함유하는 의약 및 그 제조 방법 | |
| CN116355846B (zh) | 一种质量稳定可控的扩增活化淋巴细胞的方法及其用于防治神经科疾病中的用途 | |
| RU2197984C1 (ru) | Способ лечения различных форм туберкулеза легких, в том числе резистентных к противотуберкулезной химиотерапии | |
| Song et al. | Autologous stem cell transplantation for systemic lupus erythematosus: report of efficacy and safety at 7 years of follow-up in 17 patients | |
| CN117159525B (zh) | Cert抑制剂在制备治疗急性髓系白血病的药物中的应用 | |
| CN112603920A (zh) | 一种中药川楝素在制备防治神经系统胶质瘤产品中的应用 | |
| US20200306302A1 (en) | Treating and inhibiting leukemia with nk-92 cells | |
| CN104998262B (zh) | Dpp4抑制剂在防治辐射诱导骨髓抑制药物中的应用 | |
| US20100129329A1 (en) | METHODS FOR USING ALDHbr CELLS TO SUPPLEMENT STEM CELL TRANSPLANTATION | |
| Lipton | Peripheral blood as a stem cell source for hematopoietic cell transplantation in children: is the effort in vein? | |
| CN119776283B (zh) | Car-t细胞培养方法及其在肿瘤治疗中的应用 | |
| CN101283996B (zh) | 右旋蛋氨酸在制备防治辐射诱导骨髓抑制药物中的应用 | |
| CN107243006B (zh) | Amd3100在制备治疗和/或预防恶液质的药物中的应用 | |
| CN111529539A (zh) | 一种原人参二醇在制备药物中的用途 | |
| WO2025225578A1 (ja) | 癌治療剤 | |
| CN110215460B (zh) | 一种抗肿瘤的联用组合药物 | |
| JPWO2009041573A1 (ja) | 頭頚部癌の治療に用いる、腫瘍栄養動脈に投与される抗癌細胞組成物の使用 | |
| CN105534999A (zh) | 一种用于治疗肿瘤的药物组合物及其应用 | |
| Chua | The Role of Stem Cells in Cancer Treatments. | |
| TW202541820A (zh) | 自然殺傷細胞的新型製備方法及利用其的肝癌治療方法 | |
| CN120732882A (zh) | 虫草素在制备提升免疫力低下的肿瘤患者的外周血免疫指标药物中的用途 | |
| CN107281177A (zh) | 促进造血干细胞归巢和植入的方法 |